Lupin Receives Approval From U.S. FDA For Allopurinol And Tentative For Sitagliptin Tablets

Lupin Receives Approval From U.S. FDA For Allopurinol And Tentative For Sitagliptin Tablets

These products will be manufactured at Lupin’s Pithampur facility in India.

FPJ Web DeskUpdated: Friday, December 15, 2023, 04:43 PM IST
article-image
Lupin Receives Approval From USFDA For Varenicline Tablets | Image: Wikipedia (Representative)

Global pharma major Lupin Limited (Lupin) on Friday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Allopurinol Tablets USP, 100 mg and 300 mg to market a generic bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zyloprim Tablets, 100 mg, and 300 mg, of Casper Pharma, LLC.

It also received U.S. FDA tentative approval for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg to market a generic equivalent of Januvia Tablets, 25 mg, 50 mg, and 100 mg, of Merck Sharp and Dohme Corp. (Merck), the company announced through an exchange filing.

These products will be manufactured at Lupin’s Pithampur facility in India.

About Allopurinol Tablets

Allopurinol Tablets USP, 100 mg and 300 mg are indicated for the management of:

i) Adult patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).

ii) Adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.

iii) Adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes

About Sitagliptin Tablets

Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Estimated annual sales

Allopurinol Tablets had estimated annual sales of USD 88.1 million in the U.S. (IQVIA MAT October 2023) and Sitagliptin Tablets had estimated annual sales of USD 5789.3 million in the U.S. (IQVIA MAT October 2023).

Lupin Limited shares

The shares of Lupin Limited on Friday at 3:30 pm IST were at Rs 1,250, down by 0.51 percent.

RECENT STORIES

Ambani Family Embarks On Anna Seva Ahead Of Anant-Radhika's Pre-Wedding Celebrations In Jamnagar

Ambani Family Embarks On Anna Seva Ahead Of Anant-Radhika's Pre-Wedding Celebrations In Jamnagar

YouTuber Rajaram Prasad's Journey Of Informing Millions

YouTuber Rajaram Prasad's Journey Of Informing Millions

Air India Wheelchair Fiasco: DGCA Slaps ₹30 Lakh Fine On Carrier For Incident Involving Elderly...

Air India Wheelchair Fiasco: DGCA Slaps ₹30 Lakh Fine On Carrier For Incident Involving Elderly...

Telecom Firms Need Not Deduct Tax At Source On Profits To Be Made By Their Distributors: SC

Telecom Firms Need Not Deduct Tax At Source On Profits To Be Made By Their Distributors: SC

The New Knight: Sunil Mittal's Net Worth, Philanthropy, Knighthood And More

The New Knight: Sunil Mittal's Net Worth, Philanthropy, Knighthood And More